<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39347901</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1869-6953</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Diabetes therapy : research, treatment and education of diabetes and related disorders</Title><ISOAbbreviation>Diabetes Ther</ISOAbbreviation></Journal><ArticleTitle>An SMS-Guided Basal Insulin Titration in People with Type 2 Diabetes New on Insulin.</ArticleTitle><Pagination><StartPage>2429</StartPage><EndPage>2441</EndPage><MedlinePgn>2429-2441</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13300-024-01650-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The shortage of general practitioners (GPs) and the increasing prevalence of type 2 diabetes create significant pressure on primary healthcare services. To enable that medical services are available to all that need it, innovative solutions are needed. One of those, a Short Message Service (SMS)-supported basal insulin titration service is investigated in this study. The primary objective was to determine the percentage of subjects who achieved stable fasting blood glucose (FBG) within their individual target range with this service after week 16.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This single-arm, 16-week study aimed to enroll 111 adults diagnosed with type 2 diabetes that needed insulin. The study subjects measured their FBG 4 consecutive days to establish a baseline, then received SMS prompts for daily FBG measurements and evening insulin injections until their FBG stabilized within the target range. Adjusting the insulin based on the FBG. Once stabilization was achieved, subjects continued with their optimal insulin dose for the remainder of the study. Sixteen weeks after the baseline, subjects measured FBG for 4 days before visit 4, where these values were read by the healthcare provider.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of the planned 111 subjects, only 30 were enrolled, with one withdrawal prior to service activation. Challenges in subject recruitment were attributed to the COVID-19 outbreak, limited eligibility, competing studies, and new medications delaying insulin initiation. Subjects were on average 59.97 years old, had an HbA1c of 9.29% a FBG of 205.64 mg/dl, and had diabetes for 10 years. Among the 29 subjects who started the service, 72% achieved successful titration at visit 4, with a median time of 49 days. Notable improvements were observed in HbA1c levels (decreased by 1.58%) and FBG levels (decreased by 64 mg/dl) over the 16-week study period. No adverse events or device-related issues were reported.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite recruitment challenges, guided basal insulin titration holds promise for insulin therapy initiation in individuals. The findings emphasize the potential of tele-medical approaches, specifically through remote messaging, in managing diabetes and improving therapy adherence.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snel</LastName><ForeName>Tim</ForeName><Initials>T</Initials><Identifier Source="ORCID">0009-0009-9249-9972</Identifier><AffiliationInfo><Affiliation>Roche Diabetes Care Nederland B.V., Almere, The Netherlands. tim.snel@roche.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinhardt</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Roche Diabetes Care GmbH, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koenig</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Roche Diabetes Care GmbH, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pleus</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut für Diabetes-Technologie Forschungsund Entwicklungsgesellschaft mbH an der Universität Ulm, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freckmann</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut für Diabetes-Technologie Forschungsund Entwicklungsgesellschaft mbH an der Universität Ulm, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes Ther</MedlineTA><NlmUniqueID>101539025</NlmUniqueID><ISSNLinking>1869-6961</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Basal therapy</Keyword><Keyword MajorTopicYN="N">Fasting glucose</Keyword><Keyword MajorTopicYN="N">Insulin titration</Keyword><Keyword MajorTopicYN="N">SMS</Keyword><Keyword MajorTopicYN="N">Telemedicine</Keyword></KeywordList><CoiStatement>Tim Snel, Helena Koenig. and Sven Reinhardt, have a paid position at Roche Diabetes Care, a company that markets tools related to diabetes self-management. Guido Freckmann is general manager and medical director of the Institute for Diabetes Technology (Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany), which carries out clinical studies for example with medical devices for diabetes therapy on its own initiative and on behalf of various companies. G.F./IfDT have received research support, speakers’ honoraria, or consulting fees in the last 3 years from Abbott, Ascensia, Berlin Chemie, BOYDSense, Dexcom, Lilly, Novo Nordisk, Perfood, Pharmasens, Roche, Sinocare, Terumo, Ypsomed. Stefan Pleus is an employee of IDT.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39347901</ArticleId><ArticleId IdType="pmc">PMC11466967</ArticleId><ArticleId IdType="doi">10.1007/s13300-024-01650-2</ArticleId><ArticleId IdType="pii">10.1007/s13300-024-01650-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weiss J. General practitioner shortage: with structured graduate education against the crisis. Dtsch Med Wochenschr (1946). 2010;135(28–29):26. 10.1055/s-0030-1247689.</Citation><ArticleIdList><ArticleId IdType="pubmed">20640983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen MAT, Thorsen T. Increasing shortage of general practitioners in social deprived Danish communities. Ugeskr Laeger. 2014;176(11):V08130497.</Citation><ArticleIdList><ArticleId IdType="pubmed">25096838</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed A. Shortage of general practitioners in the NHS. BMJ. 2017;358: j3191. 10.1136/bmj.j3191.</Citation><ArticleIdList><ArticleId IdType="pubmed">28694250</ArticleId></ArticleIdList></Reference><Reference><Citation>Caley M, Sidhu K. Estimating the future healthcare costs of an aging population in the UK: expansion of morbidity and the need for preventative care. J Public Heal. 2011;33(1):117–22. 10.1093/pubmed/fdq044.</Citation><ArticleIdList><ArticleId IdType="pubmed">20534629</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall TM, Gallo PD, Chakrabarti R, West T, Semilla AP, Storm MV. An aging population and growing disease burden will require a large and specialized health care workforce by 2025. Heal Aff. 2017;32(11):2013–20. 10.1377/hlthaff.2013.0714.</Citation><ArticleIdList><ArticleId IdType="pubmed">24191094</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18(9):525–39. 10.1038/s41574-022-00690-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9169030</ArticleId><ArticleId IdType="pubmed">35668219</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86. 10.2337/dci22-0034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10008140</ArticleId><ArticleId IdType="pubmed">36148880</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20(2):427–37. 10.1111/dom.13088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5813232</ArticleId><ArticleId IdType="pubmed">28834075</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Wang F, Zhang X, et al. Effectiveness of internet-based interventions on glycemic control in patients with type 2 diabetes: meta-analysis of randomized controlled trials. J Méd Internet Res. 2018;20(5): e172. 10.2196/jmir.9133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5962831</ArticleId><ArticleId IdType="pubmed">29735475</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Tao H, Meng Q, Jing L. Management of endocrine disease: effects of telecare intervention on glycemic control in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Eur J Endocrinol. 2015;172(3):R93–101. 10.1530/eje-14-0441.</Citation><ArticleIdList><ArticleId IdType="pubmed">25227131</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy NK, Orzeck-Byrnes NA, Aidasani SR, et al. Transition of a text-based insulin titration program from a randomized controlled trial into real-world settings: implementation study. J Méd Internet Res. 2018;20(3): e93. 10.2196/jmir.9515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881039</ArticleId><ArticleId IdType="pubmed">29555621</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy N, Moynihan V, Nilo A, et al. The mobile insulin titration intervention (MITI) for insulin adjustment in an urban, low-income population: randomized controlled trial. J Méd Internet Res. 2015;17(7): e180. 10.2196/jmir.4716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4527003</ArticleId><ArticleId IdType="pubmed">26187303</ArticleId></ArticleIdList></Reference><Reference><Citation>Deerochanawong C, Bajpai S, Dwipayana IMP, et al. Optimizing glycemic control through titration of insulin glargine 100 U/mL: a review of current and future approaches with a focus on Asian populations. Diabetes Ther. 2017;8(6):1197–214. 10.1007/s13300-017-0322-z.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688987</ArticleId><ArticleId IdType="pubmed">29094298</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang R, Deng X. Electronic messaging intervention for management of cardiovascular risk factors in type 2 diabetes mellitus: a randomised controlled trial. J Clin Nurs. 2018;27(3–4):612–20. 10.1111/jocn.13962.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700102</ArticleId></ArticleIdList></Reference><Reference><Citation>Peimani M, Rambod C, Omidvar M, et al. Effectiveness of short message service-based intervention (SMS) on self-care in type 2 diabetes: a feasibility study. Prim Care Diabetes. 2016;10(4):251–8. 10.1016/j.pcd.2015.11.001.</Citation><ArticleIdList><ArticleId IdType="pubmed">26653014</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X, Wang Q, Yang X, et al. Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis. Diabet Med. 2011;28(4):455–63. 10.1111/j.1464-5491.2010.03180.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">21392066</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamez-Pérez HE, Author D, Cantú-Santos OM, Gutierrez-González D, González-Facio R, Romero-Ibarguengoitia ME. Effect of digital-tool-supported basal insulin titration algorithm in reaching glycemic control in patients with type 2 diabetes in Mexico. J Diabetes Sci Technol. 2021. 10.1177/19322968211034533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9631525</ArticleId><ArticleId IdType="pubmed">34323110</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortmann AL, Gallo LC, Garcia MI, et al. Dulce digital: an mHealth SMS-based intervention improves glycemic control in Hispanics with type 2 diabetes. Diabetes Care. 2017;40(10):1349–55. 10.2337/dc17-0230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5606313</ArticleId><ArticleId IdType="pubmed">28600309</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborn CY, Mulvaney SA. Development and feasibility of a text messaging and interactive voice response intervention for low-income, diverse adults with type 2 diabetes mellitus. J Diabetes Sci Technol. 2013;7(3):612–22. 10.1177/193229681300700305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869128</ArticleId><ArticleId IdType="pubmed">23759393</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer HH, Moore SL, Ginosar D, et al. Care by cell phone: text messaging for chronic disease management. Am J Manag Care. 2012;18(2):e42–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22435883</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S, Peters AL, Agy C, Menchine M. A mobile health intervention for inner city patients with poorly controlled diabetes: proof-of-concept of the TExT-MED Program. Diabetes Technol Ther. 2012;14(6):492–6. 10.1089/dia.2011.0252.</Citation><ArticleIdList><ArticleId IdType="pubmed">22524591</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj HS, Venn K, Ye C, Aronson R. Randomized trial of long-acting insulin glargine titration web tool (LTHome) versus enhanced usual therapy of glargine titration (INNOVATE Trial). Diabetes Technol Ther. 2016;18(10):610–5. 10.1089/dia.2016.0182.</Citation><ArticleIdList><ArticleId IdType="pubmed">27652718</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:308–3086.</Citation><ArticleIdList><ArticleId IdType="pubmed">14578243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Wang M, Zhao Y. SAR342434 - an insulin biosimilar for the treatment of type II diabetes. Expert Opin Biol Ther. 2018;18(11):1107–12. 10.1080/14712598.2018.1533548.</Citation><ArticleIdList><ArticleId IdType="pubmed">30295083</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi KD, Jha S, Panda M, et al. 138-LB: digital-tool-supported basal insulin (BI) titration: real-world effectiveness of my dose coach in India. Diabetes. 2019. 10.2337/db19-138-lb.</Citation></Reference><Reference><Citation>Hermanns N, Ehrmann D, Finke-Groene K, et al. Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trial. Lancet Reg Health Eur. 2023;33: 100702. 10.1016/j.lanepe.2023.100702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10636267</ArticleId><ArticleId IdType="pubmed">37954005</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies M, Bain S, Charpentier G, et al. A randomized controlled, treat-to-target study evaluating the efficacy and safety of insulin glargine 300 U/ml (Gla-300) administered using either device-supported or routine titration in people with type 2 diabetes. J Diabetes Sci Technol. 2019;13(5):881–9. 10.1177/1932296818821706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6955447</ArticleId><ArticleId IdType="pubmed">30646755</ArticleId></ArticleIdList></Reference><Reference><Citation>Grdinovac K, Dc R, Ta L, Levin P, Sysko R. 122-LB: iSage: successful basal insulin titration managed by a prescription-only digital therapy for T2DM. Diabetes. 2019. 10.2337/db19-122-lb.</Citation></Reference><Reference><Citation>Philis-Tsimikas A, Al F, Bastian A, et al. 202-OR: basal insulin digital titration app vs. enhanced paper titration tool: a randomized control study. Diabetes. 2020. 10.2337/db20-202-or.</Citation></Reference><Reference><Citation>Khunti K, Giorgino F, Berard L, Mauricio D, Harris SB. The importance of the initial period of basal insulin titration in people with diabetes. Diabetes Obes Metab. 2020;22:722–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187252</ArticleId><ArticleId IdType="pubmed">31865632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz-Zúñiga Á, Simó-Servat O, Amigó J, Sánchez M, Morer C, Franch-Nadal J, Hernández C. Efficacy of insulin titration driven by SMS in improving glycemic control in people with type 2 diabetes. J Clin Med. 2023;12(19):6364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10573537</ArticleId><ArticleId IdType="pubmed">37835008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>